Skip to Content

pyrazinamide FDA Alerts

The FDA Alert(s) below may be specifically about pyrazinamide or relate to a group or class of drugs which include pyrazinamide.

MedWatch Safety Alerts are distributed by the FDA and published by Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.

Recent FDA Alert(s) for pyrazinamide

Rifampin plus Pyrazinamide for Treatment of Latent Tuberculosis Infection (LTBI)

Aug 12, 2003

Audience: Infectious Disease and other healthcare professionals

The Centers for Disease Control and Prevention (CDC) notified healthcare professionals of revised recommendations against the use of rifampin plus pyrazinamide for treatment of latent tuberculosis infection, due to high rates of hospitalization and death from liver injury associated with the combined use of these drugs.

[August 8, 2003 Letter - CDC]
[August 8, 2003 MMWR Article - CDC]

More pyrazinamide Resources